Publicaciones en las que colabora con Javier Crespo García (17)

2024

  1. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome

    Journal of Hepatology

  2. Programa de certificación de Centros de Adicciones para la eliminación del virus de la hepatitis C en España. Proyecto HepCelentes

    Adicciones: Revista de socidrogalcohol, Vol. 36, Núm. 2, pp. 129-144

  3. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

    Hepatology, Vol. 77, Núm. 4, pp. 1095-1105

  2. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

2022

  1. Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study

    Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 1, pp. 131-143

2021

  1. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old

    Clinical Pharmacology and Therapeutics, Vol. 109, Núm. 4, pp. 1147-1158

  2. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  3. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

2018

  1. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349

  2. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))

    Gastroenterologia y Hepatologia

  3. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502

2015

  1. Application of the Barcelona clinic liver cancer therapeutic strategy and impact on survival

    United European Gastroenterology Journal, Vol. 3, Núm. 3, pp. 284-293

  2. High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain

    Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486

2001

  1. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis?

    Obesity Surgery, Vol. 11, Núm. 3, pp. 254-257

  2. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

    Hepatology, Vol. 34, Núm. 6, pp. 1158-1163